- Home
- HTGC vs DNLI Comparison
HTGC vs DNLI Comparison
Compare HTGC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- DNLI
- Stock Information
- Founded
- HTGC 2003
- DNLI 2013
- Country
- HTGC United States
- DNLI United States
- Employees
- HTGC 100
- DNLI N/A
- Industry
- HTGC Investment Managers
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HTGC Finance
- DNLI Health Care
- Exchange
- HTGC Nasdaq
- DNLI Nasdaq
- Market Cap
- HTGC 3.5B
- DNLI 3.3B
- IPO Year
- HTGC 2005
- DNLI 2017
- Fundamental
- Price
- HTGC $20.97
- DNLI $22.99
- Analyst Decision
- HTGC Buy
- DNLI Strong Buy
- Analyst Count
- HTGC 8
- DNLI 13
- Target Price
- HTGC $20.88
- DNLI $38.00
- AVG Volume (30 Days)
- HTGC 813.2K
- DNLI 1.1M
- Earning Date
- HTGC 02-13-2025
- DNLI 02-25-2025
- Dividend Yield
- HTGC 9.13%
- DNLI N/A
- EPS Growth
- HTGC 1.34
- DNLI N/A
- EPS
- HTGC 2.01
- DNLI N/A
- Revenue
- HTGC $494,410,000.00
- DNLI N/A
- Revenue This Year
- HTGC $10.55
- DNLI N/A
- Revenue Next Year
- HTGC $5.06
- DNLI $651.24
- P/E Ratio
- HTGC $10.43
- DNLI N/A
- Revenue Growth
- HTGC 12.81
- DNLI 204.74
- 52 Week Low
- HTGC $16.95
- DNLI $14.56
- 52 Week High
- HTGC $21.78
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- HTGC 61.19
- DNLI 53.06
- Support Level
- HTGC $20.65
- DNLI $21.55
- Resistance Level
- HTGC $21.25
- DNLI $24.29
- Average True Range (ATR)
- HTGC 0.27
- DNLI 1.22
- MACD
- HTGC -0.00
- DNLI 0.17
- Stochastic Oscillator
- HTGC 75.00
- DNLI 73.14
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.